Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalCardiovascularAortic DissectionTrial Update

Study on Modified Antegrade Cerebral Perfusion in Aortic Dissection Surgery

The evaluation of modified antegrade cerebral perfusion (MACP) in aortic dissection surgery could lead to significant changes in surgical techniques and practices. This may affect the competitive landscape for cardiovascular devices and necessitate updates in training programs for surgeons.

Published: July 5, 2026
Updated: July 5, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Aortic Dissection
Asset: Study
Trial SummaryCLN

Phase III

Cardiovascular / Aortic Dissection

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The evaluation of modified antegrade cerebral perfusion (MACP) in aortic dissection surgery could lead to significant changes in surgical techniques and practices. This may affect the competitive landscape for cardiovascular devices and necessitate updates in training programs for surgeons.

Why it matters

The evaluation of modified antegrade cerebral perfusion (MACP) in aortic dissection surgery could lead to significant changes in surgical techniques and practices. This may affect the competitive landscape for cardiovascular devices and necessitate updates in training programs for surgeons.

What changed

Trial Update

Analysis

The study evaluates the feasibility of modified antegrade cerebral perfusion (MACP) in emergency total arch replacement for acute type A aortic dissection.

The evaluation of modified antegrade cerebral perfusion (MACP) in aortic dissection surgery could lead to significant changes in surgical techniques and practices. This may affect the competitive landscape for cardiovascular devices and necessitate updates in training programs for surgeons.

Monitor further studies validating MACP's effectiveness and any shifts in surgical guidelines or practices.

Related companies & assets

Assets

  • Study →
  • cardiovascular surgical device manufacturers →

Sources & Humanexa intelligence

Source links

  • Study on Modified Antegrade Cerebral Perfusion in Aortic Dissection Surgery ↗

Related Humanexa pages

  • Study on Modified Antegrade Cerebral Perfusion in Aortic Dissection Surgery →

Related signals

Trial SummaryCLN

Phase I

autoimmune neurologic disease market

Status

Initiated

Sponsor

Kite Pharma

Signal Score

8.2

Clinicalhigh signal

KITE-363 Phase 1 Study Initiated for Autoimmune Neurologic Diseases

Kite, Gilead Company, is conducting Phase 1 study to evaluate the safety and efficacy of KITE-363 in patients with relapsed/refractory autoimmune neurologic diseases.

July 5, 2026Read signal →
Trial SummaryCLN

Phase III

Rheumatology / Rheumatoid Arthritis

Status

Active

Signal Score

8.2

Clinicalhigh signal

Evaluation of OPTIBIO Tool for Medication Reduction in Rheumatoid Arthritis

A clinical trial is assessing the OPTIBIO predictive tool to guide medication reduction in RA patients in remission.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.